企業プロフィール
X4 Pharmaceuticals 株価・ニュース・カタリスト
- ティッカー:
- XFOR
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
4.30 USD (+1.90%)
終値
最終更新: 2026年8月17日
381M USD
時価総額
株価変動の要因
As of Aug 17, 2026, XFOR closed up 1.90% at $4.30. No new same-company headline was identified in the current news window.
企業概要
Rare Hematology Focus
X4 Pharmaceuticals develops therapies for rare disorders in which dysregulated CXCR4 signaling contributes to abnormal retention of immune cells in bone marrow. Its lead molecule, mavorixafor, is an oral CXCR4 antagonist designed to mobilize neutrophils into circulation.
Chronic Neutropenia Development
Mavorixafor is being evaluated in the global pivotal 4WARD Phase 3 trial for congenital, acquired primary autoimmune and idiopathic chronic neutropenia. The study tests once-daily mavorixafor, with or without G-CSF, in patients who experience recurrent or serious infections.
Approved WHIM Syndrome Product
Mavorixafor is approved as XOLREMDI for WHIM syndrome, including authorization in the European Union. X4 has partnered with Norgine for European commercialization, giving the company a partner-led route to expand access while concentrating internal resources on clinical development.
今後のカタリスト
- Completion of enrollment in the 4WARD Phase 3 chronic neutropenia trial expected by the end of the third quarter of 2026.
- Transfer of the European XOLREMDI marketing authorization to Norgine planned later in 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。